Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01964755 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
A Phase 2 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01964755 is a Phase 2 study that was terminated before completion, run by University of Miami. The registered enrollment target is 6 participants.
The verdict
NCT01964755, a Phase 2 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
By combining a variety of agents that potentiate Zidovudine (ZDV), the investigators hope to induce remission in this generally fatal disease. Most therapies for aggressive B cell lymphomas are based upon intensive chemotherapeutic regimens, expensive modalities (bone marrow transplant, Rituximab), or experimental approaches (gene therapy, cytotoxic T cell infusion) that are difficult to implement in heavily pre-treated patients. Therapy for relapsed aggressive B cell lymphomas is very poor. Even curable lymphomas such as Burkitt Lymphoma (BL) and Hodgkin lymphoma are extremely difficult to treat in relapse and/or after stem cell transplant failure. The investigators propose a novel therapeutic approach that exploits the presence of Epstein-Barr virus (EBV) in lymphomas; antiviral mediated suppression of NF-kB and disruption of viral latency.
Interventions
- DRUG Doxorubicin
- DRUG Leucovorin
- DRUG Zidovudine
- DRUG Methotrexate
- BIOLOGICAL Hydroxyurea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-04-21 |
| Est. Completion | 2018-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01964755
The ClinicalTrials.gov registry entry for NCT01964755 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Doxorubicin is the first listed.
NCT01964755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01964755 about?
NCT01964755 is a clinical study titled "Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma". By combining a variety of agents that potentiate Zidovudine (ZDV), the investigators hope to induce remission in this generally fatal disease. Most therapies for aggressive B cell lymphomas are based upon intensive chemotherapeutic regimens, expensive modalities (bone marrow transplant, Rituximab), ...
What is the current status of trial NCT01964755?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2009-04-21. Estimated completion is 2018-06-07.
What interventions are being tested in trial NCT01964755?
The interventions under investigation include: Doxorubicin (DRUG), Leucovorin (DRUG), Zidovudine (DRUG), Methotrexate (DRUG), Hydroxyurea (BIOLOGICAL).
Who is sponsoring clinical trial NCT01964755?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.